WHWK News and Press, Whitehawk Therapeutics Inc.

Whitehawk Therapeutics to Participate in Jones Trading Post-AACR Fireside Chat Series PR Newswire MORRISTOWN, N.J. , April 16, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to e...

2026-04-16 14:30:45 ET More on Whitehawk Therapeutics Seeking Alpha’s Quant Rating on Whitehawk Therapeutics Historical earnings data for Whitehawk Therapeutics Financial information for Whitehawk Therapeutics Read the full article on Seeking Alpha ...

Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as a Highly Expressed, Clinically Relevant Target for Gynecologic Cancers at SGO 2026 PR Newswire MUC16 is the highest-expressing ADC target in ovarian cancer, at least two-fold higher than other emerging targets ...

Whitehawk Therapeutics to Highlight its Next-Generation ADC Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026 PR Newswire MORRISTOWN, N.J. , March 17, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncolo...

2026-03-12 15:10:45 ET More on Whitehawk Therapeutics Seeking Alpha’s Quant Rating on Whitehawk Therapeutics Historical earnings data for Whitehawk Therapeutics Financial information for Whitehawk Therapeutics Read the full article on Seeking Alpha ...

Whitehawk Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights PR Newswire Actively recruiting Phase 1 trials for PTK7-targeted antibody-drug conjugate (ADC) HWK-007 and MUC16-targeted ADC HWK-016 HWK-206 on track for planned IND submiss...

2026-03-05 14:41:06 ET The last time I spoke about Day One Biopharmaceuticals ( DAWN ), it was regarding a Seeking Alpha article entitled " Day One Biopharmaceuticals: Mersana Acquisition Ignites March Towards Unmet Need ." I noted that this company had completed its acquisition o...

Whitehawk Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference PR Newswire MORRISTOWN, N.J. , Feb. 18, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced tec...

Whitehawk Therapeutics Advances to Clinical Stage with IND Clearance for HWK-007 and Announces IND Submission for HWK-016 PR Newswire Actively recruiting Phase 1 trial for PTK7-targeted antibody-drug conjugate (ADC) HWK-007 IND submitted mid-December 2025 for MUC16-targeted ...

Whitehawk Therapeutics Appoints Margaret Dugan, MD, as Chief Medical Officer PR Newswire Dr. Dugan brings extensive clinical development leadership to Whitehawk as ADC programs near the clinic MORRISTOWN, N.J. , Dec. 1, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (N...